Breast Cancer Clinical Trial
StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients
Summary
This clinical trial studies the effect of StrataXRT in preventing and treating radiation dermatitis in breast cancer or head and neck cancer patients. Radiotherapy is often associated with multiple side effects. These side effects can cause patient injury and make it difficult to complete treatment. For example, radiation dermatitis or skin damage may result in severe skin peeling and skin irritation. Depending on the location of radiation, the skin damage can cause problems and be tough to heal. This trial aims to see whether StrataXRT may help to prevent dermatitis after radiation therapy.
Full Description
PRIMARY OBJECTIVE:
I. Compare efficacy of silicone-based film forming topical gel (StrataXRT) versus (vs.) standard of care skin maintenance.
SECONDARY OBJECTIVES:
I. Evaluate overall effectiveness of StrataXRT. II. Evaluate post-radiation therapy (RT) recovery time for StrataXRT compared to standard of care.
EXPLORATORY OBJECTIVES:
I. To assess patient reported outcomes. II. Evaluate cost of StrataXRT for management of radiation dermatitis compared to standard of care skin maintenance.
III. Evaluate the reduction in RT interruption/extension of overall duration of receiving RT based on the reduced skin toxicity.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients apply StrataXRT topically to the affected area once or twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =< 1.
ARM II: Patients receive standard of care including calendula and/or petrolatum-mineral oil-lanolin-ceresin ointment (Aquaphor) applied 2-6 times daily plus hydrogel or silver sulfadiazine (Silvadene) or topical corticosteroids applied twice daily starting from the first dose of radiation therapy until dermatitis has returned to grade =< 1.
After completion of study, patients are followed up at 6 days and 3 weeks post-RT.
Eligibility Criteria
Inclusion Criteria:
Patients will be adult (> age of 18) patients. Both men and women and members of all races and ethnic groups will be included
Histologically confirmed malignancy for which standard curative measures in conjunction with radiotherapy are indicated to the following sites: whole breast/chest-wall for post-surgical radiotherapy or bilateral neck (levels one through six) for head and neck cancer
All head and neck cancer patients should have the left and right neck treated to the same dose when receiving bilateral neck irradiation
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
Clinically evident skin involvement of malignancy
Thin patients with nodal involvement requiring bolus
Patients with significant unshaven facialor chest wall hair compromising film application
Evidence of active cellulitis or wound infection involving anticipated treatment site
History of prior radiotherapy to involved site within 5 cm of anticipated treatment field
Eastern Cooperative Oncology Group (ECOG) performance status >= 3
Patients receiving concurrent capecitabine
Patient with skin grafts over treatment site(s)
Presence of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. (i.e. schizophrenia, autism, temporary housing during treatment, scheduling conflict immediately after treatment. This will need to be assessed prior to consent
Actual or perceived inability to reliably apply StrataXRT to the patients treatment field in the home environment
Anticipated or actual use of other non-study topical medications or remedies in the treatment field
Vulnerable populations (pregnant women, decisionally impaired adults, and prisoners) will be excluded from the study
Patients receiving ultra-hypofractionated radiation to the breast
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Portland Oregon, 97239, United States More Info
Principal Investigator
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.